Page last updated: 2024-08-16

tetrahydropalmatine and Bone Loss, Osteoclastic

tetrahydropalmatine has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cao, L; Chen, H; Chen, X; Cui, J; Fang, C; Hu, Y; Jiang, H; Li, X; Qin, L; Song, H; Su, J; Wang, L; Wang, S; Wang, Y; Weng, W; Zhi, X; Zhou, Q	1

Other Studies

1 other study(ies) available for tetrahydropalmatine and Bone Loss, Osteoclastic

Article	Year
l-tetrahydropalmatine suppresses osteoclastogenesis in vivo and in vitro via blocking RANK-TRAF6 interactions and inhibiting NF-κB and MAPK pathways. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:1 Topics: Animals; Anti-Arrhythmia Agents; Berberine Alkaloids; Bone Resorption; Cell Differentiation; Female; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Osteoblasts; Osteogenesis; Protein Interaction Domains and Motifs; Receptor Activator of Nuclear Factor-kappa B; TNF Receptor-Associated Factor 6	2020

Article

Year

l-tetrahydropalmatine suppresses osteoclastogenesis in vivo and in vitro via blocking RANK-TRAF6 interactions and inhibiting NF-κB and MAPK pathways.

Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:1

Topics: Animals; Anti-Arrhythmia Agents; Berberine Alkaloids; Bone Resorption; Cell Differentiation; Female; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Osteoblasts; Osteogenesis; Protein Interaction Domains and Motifs; Receptor Activator of Nuclear Factor-kappa B; TNF Receptor-Associated Factor 6

2020